Clinical application of exosomal miRNA as biomarker in breast cancer

doi:10.3760/cma.j.issn.1673-422X.2019.07.007

Abstract

Abstract: MicroRNA (miRNA) has a tumorspecific expression profile and plays an important role in the occurrence and progression of tumors. It is protected from RNase in body fluids through the inclusion of exosomes and translocates genetic information horizontally between breast cancer cells. Recent studies on exosome miRNA have found that it is closely related to the occurrence, diagnosis, treatment and prognosis of breast cancer. The indepth study in this field can provide theoretical basis for the clinical application of exosome miRNA as a biomarker for breast cancer.

Key words: Breast neoplasms, Exosomes, MicroRNAs, Biomarker

Cao Lixia, Shi Zhendong, Liu Jingjing, Zhang Jin. Clinical application of exosomal miRNA as biomarker in breast cancer[J]. Journal of International Oncology, 2019, 46(7): 423-426.

References

［1］ Harbeck N, Gnant M. Breast cancer［J］. Lancet, 2017, 389(10074): 11341150. DOI: 10.1016/S01406736(16)318918. ［2］ Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparibcarboplatin treatment in breast cancer［J］. N Engl J Med, 2016, 375(1): 2324. DOI: 10.1056/NEJMoa1513749. ［3］ Joyce DP, Kerin MJ, Dwyer RM. Exosomeencapsulated microRNAs as circulating biomarkers for breast cancer［J］. Int J Cancer, 2016, 139(7): 14431448. DOI: 10.1002/ijc.30179. ［4］ Sun Y, Liu J. Potential of cancer cellderived exosomes in clinical application: a review of recent research advances［J］. Clin Ther, 2014, 36(6): 863872. DOI: 10.1016/j.clinthera.2014.04.018. ［5］ Lee JH, Kim JA, Jeong S, et al. Simultaneous and multiplexed detection of exosome microRNAs using molecular beacons［J］. Biosens Bioelecton, 2016, 86: 202210. DOI: 10.1016/j.bios.2016.06.058. ［6］ Hellwinkel JE, Redzic JS. Gliomaderived extracellular vesicles selectively suppress immune responses［J］. Neuro Oncol, 2016, 18(4): 497506. DOI: 10.1093/neuonc/nov170. ［7］ Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: celltocell mediators of metastasis［J］. Cancer Cell, 2016, 30(6): 836848. DOI: 10.1016/j.ccell.j.ccell.2016.10.009. ［8］ Kalluri R. The biology and function of exosomes in cancer［J］. J Clin Invest, 2016, 126(4): 12081215. DOI: 10.1172/JCI81135. ［9］ Frassanito MA, De Veirman K, Desantis V. Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients［J］. Leukemia, 2016, 30(3): 640648. DOI: 10.1038/leu.2015.289. ［10］ Jia Y, Chen Y, Wang Q, et al. Exosome: emerging biomarker in breast cancer［J］. Oncotarget, 2017, 8(25): 4171741733. DOI: 10.18632/oncotarget.16684. ［11］ Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver antimiR214 to reverse chemoresistance to cisplatin in gastric cancer［J］. Mol Ther, 2018, 26(3): 774783. DOI: 10.1016/j.ymthe. ［12］ Wang T, Fang L, Zhao F, et al. Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus［J］. J Virol, 2018, 92(4). pii: e0173417. DOI: 10.1128/JVI.0173417. ［13］ Moore C, Kosgodage U, Lange S, et al. The emerging role of exosome and microvesicle (EMV) based cancer therapeutics and immunotherapy［J］. Int J Cancer, 2017, 141(3): 428436. DOI: 10.1002/ijc.30672. ［14］ Gorski SA, Vogel J, Doudna JA. RNAbased recognition and targeting: sowing the seeds of specificity［J］. Nat Rev Mol Cell Biol, 2017, 18(4): 215228. DOI: 10.1038/nrm.2016.174. ［15］ Ohno S, Kuroda M. Exosomemediated targeted delivery of miRNAs［J］. Methods Mol Biol, 2016, 1448: 261270. DOI: 10.1007/9781493937530_19. ［16］ Hannafon BN. Plasma exosome microRNAs are indicative of breast cancer［J］. Breast Cancer Res, 2016, 18(1): 90. DOI: 10.1186/s130580160753x. ［17］ Naughton E. Exosomeencapsulated microRNA451a as a circulating biomarker for breast cancer［J］. Ir J Med Sci, 2017, 186 (Suppl 1): S1S39. DOI: 10.1007/s1184501615325. ［18］ Stevic I, Müller V, Weber K, et al. Specific microRNA signatures in exosomes of triplenegative and HER2positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial［J］. BMC Med, 2018, 16(1): 179. DOI: 10.1186/s129160181163y. ［19］瞿望. 采用AT方案新辅助化疗的Luminal A型乳腺癌患者血浆外泌体microRNA特征研究［D］. 北京: 北京协和医学院中国医学科学院, 2017. ［20］ Zhao L, Liu W, Xiao J, et al. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance［J］. Cancer Lett, 2015, 356(2 Pt B): 339346. DOI: 10.1016/j.canlet.2014.10.027. ［21］ Eichelser C, Stuckrath I, Muller V, et al. Increased serum levels of circulating exosomal microRNA373 in receptornegative breast cancer patients［J］. Oncotarget, 2014, 5(20): 96509663. DOI: 10.18632/oncotarget.2520. ［22］ Yoshikawa M. Exosomeencapsulated microRNA2233p as a minimally invasive biomarker for the early detection of invasive breast cancer［J］. Oncol Lett, 2018, 15(6): 95849592. DOI: 10.3892/ol.2018.8457. ［23］ O′Brien K, Lowry MC. miR134 in extracellular vesicles reduces triplenegative breast cancer aggression and increases drug sensitivity［J］. Oncotarget, 2015, 6(32): 3277432789. DOI: 10.18632/oncotarget.5192. ［24］ Hu W, Tan C, He Y, et al. Functional miRNAs in breast cancer drug resistance［J］. Onco Targets Ther, 2018, 11: 15291541. DOI: 10.2147/OTT.S152462. ［25］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 6473. DOI: 10.3816/CBC.2010.n.009. ［26］ Zhou W, Fong MY, Min Y, et al. Cancersecreted miR105 destroys vascular endothelial barriers to promote metastasis［J］. Cancer Cell, 2014, 25(4): 501515. DOI: 10.1016/j.ccr.2014.03.007. ［27］ Singh R, Pochampally R, Watabe K, et al. Exosomemediated transfer of miR10b promotes cell invasion in breast cancer［J］. Mol Cancer, 2014, 13: 256. DOI: 10.1186/1476459813256. ［28］ Sueta A, Yamamoto Y, Tomiguchi M, et al. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and norecurrence［J］. Oncotarget, 2017, 8(41): 6993469944. DOI: 10.18632/oncotarget.19482.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[7]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[8]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[9]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[10]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[11]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[12]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[13]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[14]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei. Current status of research on exosomes in malignancies [J]. Journal of International Oncology, 2023, 50(8): 484-488.
[15]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.